Institute for Clinical and Economic Review (ICER) said that GSK’s new drug, Nucala for severe asthma should be as much as 76 percent lower to justify its value.
US Food And Drug Administration Approves GSK's Drug For Severe Asthma
The drug, Nucala is administered once every four weeks by subcutaneous injection into the upper arm, thigh, or abdomen.
The drug, Nucala is administered once every four weeks by subcutaneous injection into the upper arm, thigh, or abdomen.
‘Institute for Clinical and Economic Review (ICER) reports that the GlaxoSmithKline’s drug, Nucala to treat severe asthma is not cost-effective and its price should be cut by more than half.’
The organization has reported that the GSK’s new drug, Nucala for severe asthma should be as much as 76 percent lower to justify its value. The drug should be priced at $7,800 to about $12,000 a year than its current price of $32,500 a year. GSK won the USFDA’s approval for Nucala last month which significantly reduces asthma attacks, symptoms and also decreases the need for oral steroids. The organization indicated that there is uncertainty about whether the benefits will persist over the long term because of the short duration of clinical trials.
ICER President Steven Pearson, said, “Our analyses aim to help the health care community determine what should be used, which patients benefit most, and at what price innovative treatments represent a reasonable value.”
GSK Completes Global Media Review, Awards Media Business to Omnicom's PHD and Mediacom
MediaCom is expected to retain the European element of the global media account, while PHD will retain the US business. The account is worth $1.7 billion.
MediaCom is expected to retain the European element of the global media account, while PHD will retain the US business. The account is worth $1.7 billion.
Source-Medindia
GSK Encounters Initial Resistance Following Directional Shift, Says GlobalData Analyst
GlaxoSmithKline plc (GSK) is realigning its operating structure with its corporate objectives and cashing in on its assets.
GlaxoSmithKline plc (GSK) is realigning its operating structure with its corporate objectives and cashing in on its assets.
Comic Relief and GSK Collaborates to Reduce Global Malarial Rates By 2030
Comic relief and GSK has contributed £5m and £17m respectively for reducing malaria in five endemic countries in Sub-Saharan Africa and Asia.
Comic relief and GSK has contributed £5m and £17m respectively for reducing malaria in five endemic countries in Sub-Saharan Africa and Asia.
